See the Glossary for more terms.
Several investigators have graciously agreed to let us post their exceptional applications online.
We are truly indebted to the investigators listed below, who have enabled us to deliver this widely anticipated resource to the research community.
We selected these applications as sound examples of good grantsmanship. That said, time has passed since these grantees applied; the samples may not reflect the latest application format or rules. Therefore, always follow your funding opportunity's instructions for application format. We post new samples periodically.
NB. The text of these applications is copyrighted. You may use it only for nonprofit educational purposes provided the document remains unchanged and the PI, the grantee organization, and NIAID are credited.
Depending on your local printer settings, you may need to adjust margins or page layout to print the full page.
Colin Parrish, Ph.D., of Cornell University"Structural controls of functional receptor and antibody binding to viral capsids"
Adam Ratner, M.D., M.P.H., of Columbia University"Gardnerella vaginalis: toxin production and pathogenesis"
Boris Striepen, Ph.D., of the University of Georgia"Biology of the apicomplexan plastid"
Carolina Wählby, Ph.D., of the Broad Institute"Image analysis for high-throughput C. elegans infection and metabolism assays"
The small grant (R03) supports new research projects that can be carried out in a short period of time with limited resources. They are awarded for up to two years and are not renewable. R03s are not intended for new investigators.
Chad A. Rappleye, Ph.D., of Ohio State University"Forward genetics-based discovery of Histoplasma virulence genes"
The R15 Academic Research Enhancement Awards (AREA) offer support to qualified scientists for small-scale research projects that expose undergraduate and graduate students to NIH-funded research. For information on eligibility requirements, see AREA Program Ineligible Institutions.
Geoffrey Holm, Ph.D., of Colgate University"Mechanisms and Functional Consequences of Reovirus Innate Immune Activation"
Please note that the R21 funds novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to substantially advance biomedical research. R21s are not intended for new investigators, and there is no evidence that they provide a path to an independent research career.
Steven W. Dow, DVM, Ph.D., of Colorado State University, Fort Collins"Mechanisms of enteric Burkholderia psuedomallei infection"
Joseph M. McCune, MD, Ph.D., of the University of California, San Francisco"Human immune system layering and the neonatal response to vaccines"
Peter John Myler, Ph.D., and Marilyn Parsons, Ph.D., of the Seattle Biomedical Research Institute"Ribosome profiling of Trypanosoma brucei"
Howard T. Petrie, of Scripps Florida"Lymphoid signals for stromal growth and organization in the thymus."
Michael N. Starnbach, Ph.D., of Harvard University Medical School"Alteration of host protein stability by Legionella"
The R21/R33 supports a two-phased award without a break in funding. It begins with the R21 phase for milestone-driven exploratory or feasibility studies with a possible transition to the R33 phase for expanded development. Transition to the second phase depends on several factors, including the achievement of negotiated milestones.
Stephen Dewhurst, Ph.D., of the University of Rochester"The semen enhancer of HIV infection as a novel microbicide target"
The SBIR (R43/R44) and STTR (R41/R42) programs support domestic small businesses to engage in research and development with the potential for commercialization.
Timothy C. Fong of Cellerant Therapeutics, Inc."Novel indication for myeloid progenitor use: Induction of tolerance" (STTR Phase I / R41)
Jose M. Galarza of Technovax, Inc."Broadly protective (universal) virus-like particle (VLP) based influenza vaccine" (SBIR Phase I / R43)
Patricia Garrett of Immunetics, Inc."Rapid Test for Recent HIV Infection" (SBIR Phase II / R44)
Michael J. Lochhead of MBio Diagnostics, Inc."Point-of-Care HIV Antigen/Antibody Diagnostic Device" (SBIR Phase II / R44)
Kenneth Coleman of Arietis Corporation"Antibiotics for Recalcitrant Infection" (SBIR Fast-Track)
*Dr. Mark Poritz submitted the original grant application. In the course of the first year of funding, Dr. Andrew Hemmert took on increasing responsibility for the work. For the grant renewal Dr. Poritz proposed that Dr. Hemmert replace him as the PI.
The F31-Diversity supports predoctoral students from underrepresented racial and ethnic groups, those with disabilities, and those from disadvantaged backgrounds. It also provides individualized, mentored research training from outstanding faculty sponsors.
Adjoa R. Smalls-Mantey of Columbia University Health Sciences"Characterization of Antibody-Dependent Cellular Cytotoxicity in HIV Infection"
Juan Calix of University of Alabama at Birmingham"The role of wcjE disruption in pneumococcal serotype 11A humoral escape"
For information about preparing the forms and page limits:
If you have knowledge to share or want more information on this topic, email firstname.lastname@example.org with this link and your message. Thanks for helping us clarify and expand our knowledge base.
Last Updated March 30, 2016
Last Reviewed June 05, 2015